Heranova Lifesciences Debuts with Nearly $10M Seed Funding to Advance Global Women's Health Solutions

VCBeat has learned that Heranova Lifesciences Holding (hereinafter referred to as “Heranova”) announced on March 8 the completion of a seed funding round totaling nearly $10 million. Heranova is dedicated to advancing the development and commercialization of innovative solutions for women’s health worldwide.This round of financing will be primarily used to advance the company’s commercialization efforts in the Asia-Pacific region, including the market launch of its globally first-in-class, non-invasive molecular diagnostic test for endometriosis, innovative diagnostic and therapeutic products for pregnancy and childbirth, and other obstetrics and gynecology pharmaceuticals.The company is also actively pursuing early-stage development of innovative drugs for endometriosis and gynecological inflammation, while collaborating with global partners to expand innovative solutions for other key obstetrics and gynecology indications. This round of financing was co-led by DF Life Science Capital and Sinovation Ventures.

Ms. Penny Wan, Co-founder and Chairwoman of Heranova Lifesciences“Women play a pivotal role in modern society and economic development, yet there is a profound lack of understanding regarding the health issues faced by many women today. Over the past 10–20 years, diagnostic and therapeutic approaches have lacked meaningful innovation and improvement. As an industry leader dedicated to providing comprehensive solutions for women’s health, Heranova Lifesciences will transform this landscape by delivering end-to-end solutions that encompass diagnostics, therapeutics, medical devices, and digital platforms. Her health is our mission.”

Professor Hugh Taylor, Chief of Obstetrics and Gynecology at Yale University Hospital and Expert Member of the Scientific Advisory Board of Heranova Lifesciences“Endometriosis is one of the most prevalent diseases affecting women, yet significant unmet needs remain in its diagnosis and treatment. Globally, 176 million patients with endometriosis suffer long-term from severe pain, menstrual irregularities, and infertility. Unfortunately, even today, there is an average diagnostic delay of 6–12 years for endometriosis. We are pleased to see Heranova Lifesciences committed to addressing this critical gap with innovative solutions.”

Dr. Zhao Yining, Co-founder and CEO of Heranova Lifesciencesstated: “Providing convenient, safe, and effective integrated diagnostic and therapeutic solutions will be a key direction in the management, prevention, and treatment of women’s diseases. Our hardcore innovative products, developed through independent R&D and external collaborations, have gained recognition from multiple top global experts and can significantly enhance female patients’ experience with diagnosis and treatment.”

Heranova Lifesciences is a medical technology company dedicated to providing comprehensive, innovative solutions for women’s health issues. The company aims to address unmet medical needs in obstetrics and gynecology through an integrated, one-stop approach that combines diagnostics, pharmaceuticals, medical devices, and data. Supported by a world-class Scientific Advisory Board, Heranova Lifesciences was founded in Boston, USA, in June 2022 by a team of seasoned entrepreneurs and former executives from multinational corporations. The company operates under a US-Asia joint model, conducting research and development alongside commercialization efforts in parallel.

Dingfeng Life Sciences Capital is a subsidiary of Nang Fung Life Sciences Limited (Nang Fung Life Sciences), the global life sciences investment arm under Hong Kong’s Nang Fung Group. Dingfeng Life Sciences Capital is dedicated to identifying innovative products and technologies worldwide, establishing a portfolio of leading biopharmaceutical companies in Greater China to meet the growing healthcare demands of the global market, particularly in China. Its investment scope spans multiple related sectors, including biopharmaceuticals, medical devices, and healthcare services. The Dingfeng Life Sciences Capital team comprises seasoned life sciences investors and entrepreneurs with extensive industry experience in company formation and venture capital.

Sinovation Ventures was founded by Dr. Kai-Fu Lee in September 2009 with the mission of nurturing a new generation of innovative talent and high-tech enterprises. Headquartered in Beijing, the company maintains operations in Guangzhou, Shanghai, Nanjing, and Shenzhen. Leveraging its unique “tech venture capital” model, which integrates a professional team, an international network, and in-house technical experts, Sinovation Ventures currently manages over $3 billion in assets and has become one of China’s leading tech VC firms. In September 2016, under Dr. Lee’s leadership, Sinovation Ventures established the Artificial Intelligence Engineering Institute. The institute is dedicated to technological development, talent cultivation, and enterprise creation in the field of artificial intelligence. Sinovation Ventures focuses deeply on sectors including AI and hard technology, robotics and automation, semiconductors and chips, enterprise software, healthtech, and sustainable technology. To date, Sinovation Ventures has invested in more than 400 companies.